Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

  • Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform.
  • Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1.
  • The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial results, increasing the likelihood of FDA approval.
  • Financially, Avidity Biosciences has a strong cash position of $915.9 million, providing a cash runway into 2027 and supporting its transition to a commercial-stage biotech.
  • I rate RNA a “strong buy” due to its AOC platform, promising pipeline, and strong financials despite the inherent biotech risks.

Avidity Biosciences, Inc. (NASDAQ:RNA) specializes in targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates (AOC) platform. RNA can create therapies for previously unreachable tissues and cells with this approach. RNA’s platform provides monoclonal antibodies (mAbs) that accurately supply oligonucleotide treatments